DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Revenue	$ 447,304	$ 983,110	$ 845,402	$ 2,084,616
Deferred revenue	0		0		$ 0
SDM
Revenue			1,929	$ 3,474
TPT MedTech
Deferred revenue	$ 0		$ 0		0
Ally Pharma Member
Mezzanine stock, issued	110,000,000		110,000,000
Ownership percentage	80.00%		80.00%
Deferred revenue	$ 52,925		$ 52,925		$ 58,564